Kenvue Inc. (KVUE)
NYQ – Real Time Price. Currency in USD
17.47
+0.30 (1.75%)
At close: May 12, 2026, 4:00 PM EDT
17.49
+0.02 (0.11%)
After-hours: May 12, 2026, 7:57 PM EDT
Find any stock by ticker or company name

NYQ – Real Time Price. Currency in USD
17.47
+0.30 (1.75%)
At close: May 12, 2026, 4:00 PM EDT
17.49
+0.02 (0.11%)
After-hours: May 12, 2026, 7:57 PM EDT
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women’s health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee’s Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson’s, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson’s Baby, Johnson’s Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
| Name | Position |
|---|---|
| Dr. Caroline Tillett Ph.D. | Chief Scientific Officer |
| Mr. Amit Banati | Chief Financial Officer |
| Mr. Carlton Lawson | Group President of Europe, Middle East & Africa |
| Mr. Jonathan Halvorson | Chief Digital & Marketing Officer |
| Mr. Kirk L. Perry | CEO & Director |
| Mr. Matthew Orlando | General Counsel |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 8-K | kvue-20260507.htm |
| 2026-05-07 | 10-Q | kvue-20260329.htm |
| 2026-04-15 | 8-K | form8-k.htm |
| 2026-04-08 | DEF 14A | kvue-20260408.htm |
| 2026-02-20 | 10-K | kvue-20251228.htm |
| 2026-02-17 | 8-K | kvue-20260217.htm |
| 2026-02-12 | 8-K | form8-k.htm |
| 2026-01-29 | 8-K | kvue-20260129.htm |
| 2026-01-16 | 8-K | ef20063257_8k.htm |
| 2026-01-13 | 425 | tm263109d1_425.htm |
| Mr. Michael P. Wondrasch |
| Chief Technology & Data Officer |
| Ms. Heather R. Howlett | Chief Accounting Officer |
| Ms. Meredith Stevens | Chief Operations Officer |
| Ms. Sofya Tsinis | Head of Investor Relations |